Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
CONCLUSION: TP53mut ctDNA shows potential as a tumor-specific biomarker for treatment response monitoring in HGSOC. TP53mut ctDNA levels at 3 months post treatment has a significant prognostic utility than that of CA 125.
PMID: 30887755 [PubMed - in process]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | CT Scan | OBGYN | Ovarian Cancer | Ovaries | Serous Carcinoma | Study